The collective impact of diabetes, cardiovascular disease and obesity represents one of the biggest health challenges facing the world today. To help prevent and even preempt disease progression through targeted and aggressive intervention strategies, it is important to look at the predictive relationship between metabolic risk factors and cardiovascular disease (CVD).
Now recognized as a disease by the American Society of Endocrinology, National Cholesterol Education Program, World Health Organization and other institutions, Cardiometabolic Syndrome is a combination of conditions, including high blood pressure, elevated insulin levels, excess body fat around the waist and abnormal cholesterol levels. These cardiovascular and metabolic disorders individually and interdependently lead to an increase in the risk of heart disease, stroke and diabetes.
There are a number of risk factors recognized by the American Heart Association for the development of cardiovascular disease including:
Impaired fasting glucose
Family history of premature CVD
Each one of these risk factors is associated with increased risk for cardiovascular disease independent of the others. However, no single risk factor alone reliably discriminates between those who will develop the disease and those who will not.
PreDx Technology Enables More Precise Risk Assessment
Multivariable risk formulas, such as the Framingham risk score, have been developed to assist in estimating an individual’s absolute risk for CVD over 10 years. However, PreDx technology is based upon multi-biomarker panels that relate to very specific physiologies. Providing insight as to which pathway or which combination of pathways are putting a patient at risk for future disease enables the physician to intervene earlier with a treatment specific to the underlying mechanism.